Potential new treatment for rheumatoid arthritis

Nature India ◽  
2015 ◽  
Keyword(s):  
Rheumatoid Arthritis ◽  
New Treatment

scholarly journals New Treatment of Rheumatoid Arthritis

BMJ ◽  
1947 ◽  
Vol 2 (4519) ◽  
pp. 252-253 ◽  
Author(s):  
I. Barsi
Keyword(s):  
Rheumatoid Arthritis ◽  
New Treatment

Ultrasound-triggered perfluorocarbon-derived nanobombs for targeted therapies of rheumatoid arthritis

2019 ◽  
Vol 7 (29) ◽  
pp. 4581-4591 ◽  
Author(s):  
Bihui Zhu ◽  
Liyun Wang ◽  
Jianbo Huang ◽  
Xi Xiang ◽  
Yuanjiao Tang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Targeted Therapies ◽  
Treatment Strategy ◽  
Theranostic Agent ◽  
New Treatment

The targeted US-triggered PFC-based “nanobombs” with US used to treat the RA in this work would offer a new treatment strategy and have a great potential for the application in the areas of theranostic agent and nanomedicine treatment.

Thalidomide a promising new treatment for rheumatoid arthritis

1984 ◽  
Vol 27 (10) ◽  
pp. 1118-1121 ◽  
Author(s):  
Oscar Gutiérrez-Rodríguez
Keyword(s):  
Rheumatoid Arthritis ◽  
New Treatment

scholarly journals Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians

2019 ◽  
Vol 8 (12) ◽  
pp. 2038 ◽  
Author(s):  
Elisabeth Bendstrup ◽  
Janne Møller ◽  
Sissel Kronborg-White ◽  
Thomas Skovhus Prior ◽  
Charlotte Hyldgaard
Keyword(s):  
Rheumatoid Arthritis ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Treatment Options ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Antifibrotic Therapy ◽  
New Treatment ◽  
Diagnostic Work ◽  
Evidence Based Therapy

Interstitial lung disease (ILD) is a serious complication of rheumatoid arthritis (RA) contributing to significantly increased morbidity and mortality. Other respiratory complications, such as chronic obstructive pulmonary disease and bronchiectasis, are frequent in RA. Infections and drug toxicity are important differential diagnoses and should be considered in the diagnostic work-up of patients with RA presenting with respiratory symptoms. This review provides an overview of the epidemiology and pathogenesis of RA-ILD, the radiological and histopathological characteristics of the disease as well as the current and future treatment options. Currently, there is no available evidence-based therapy for RA-ILD, and immunosuppressants are the mainstay of therapy. Ongoing studies are exploring the role of antifibrotic therapy in patients with progressive fibrotic ILD, which may lead to a new treatment approach for subgroups of patients with RA-ILD.

scholarly journals New Treatment of Rheumatoid Arthritis

BMJ ◽  
1947 ◽  
Vol 2 (4526) ◽  
pp. 547-547 ◽  
Author(s):  
G. L. K. Pringle
Keyword(s):  
Rheumatoid Arthritis ◽  
New Treatment

scholarly journals Choline kinase inhibition in rheumatoid arthritis

2014 ◽  
Vol 74 (7) ◽  
pp. 1399-1407 ◽  
Author(s):  
M Guma ◽  
E Sanchez-Lopez ◽  
A Lodi ◽  
R Garcia-Carbonell ◽  
S Tiziani ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Joint Damage ◽  
Cartilage Destruction ◽  
Resonance Spectroscopy ◽  
Choline Kinase ◽  
Cancer Invasiveness ◽  
Established Disease ◽  
Pdgf Stimulation ◽  
Essential Enzyme ◽  
New Treatment

ObjectivesLittle is known about targeting the metabolome in non-cancer conditions. Choline kinase (ChoKα), an essential enzyme for phosphatidylcholine biosynthesis, is required for cell proliferation and has been implicated in cancer invasiveness. Aggressive behaviour of fibroblast-like synoviocytes (FLS) in rheumatoid arthritis (RA) led us to evaluate whether this metabolic pathway could play a role in RA FLS function and joint damage.MethodsCholine metabolic profile of FLS cells was determined by 1H magnetic resonance spectroscopy (1HMRS) under conditions of ChoKα inhibition. FLS function was evaluated using the ChoKα inhibitor MN58b (IC50=4.2 μM). For arthritis experiments, mice were injected with K/BxN sera. MN58b (3 mg/kg) was injected daily intraperitoneal beginning on day 0 or day 4 after serum administration.ResultsThe enzyme is expressed in synovial tissue and in cultured RA FLS. Tumour necrosis factor (TNF) and platelet-derived growth factor (PDGF) stimulation increased ChoKα expression and levels of phosphocholine in FLS measured by Western Blot (WB) and metabolomic studies of choline-containing compounds in cultured RA FLS extracts respectively, suggesting activation of this pathway in RA synovial environment. A ChoKα inhibitor also suppressed the behaviour of cultured FLS, including cell migration and resistance to apoptosis, which might contribute to cartilage destruction in RA. In a passive K/BxN arthritis model, pharmacologic ChoKα inhibition significantly decreased arthritis in pretreatment protocols as well as in established disease.ConclusionsThese data suggest that ChoKα inhibition could be an effective strategy in inflammatory arthritis. It also suggests that targeting the metabolome can be a new treatment strategy in non-cancer conditions.

New treatment possibilities in rheumatoid arthritis: REVIEW

2000 ◽  
Vol 29 (2) ◽  
pp. 73-84 ◽  
Author(s):  
Øystein FØrre, Margaretha Haugen, W
Keyword(s):  
Rheumatoid Arthritis ◽  
New Treatment
Sign in / Sign up

Export Citation Format

Share Document